COLUMN

Rare Disease Pharmaceuticals in Japan to See New Demand for Skilled Human Resources

July 20, 2018
Philip Carrigan According to recent statistics on the prevalence rate of rare diseases, per 10,000 individuals, the United States has 7.5, Japan 4, and Australia 1.2 patients with rare diseases. The most important challenge drug developers and pharmaceutical companies face…

To read the full story

COLUMN

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…